500 NORTH BEACON STREET, 4TH FLOOR, WATERTOWN, MA
Announces First Quarter 2026 Financial Results and Provides a Business Update
Annual Report to Security Holders
News, Articles of Incorporation
Announces Fourth Quarter and Full Year 2025 Financial Results and Provides a Business Update
Kymera Therapeutics Enters $500 Million Sales Agreement with TD Cowen
Outlines Key 2026 Objectives and Strategy to Advance Industry Leading Portfolio of Oral Immunology Programs
Announces Pricing of Upsized $602 Million Public Offering
Reg. FD
Q1
FY 2024
Q3
Q2
FY 2023
Registration Statement for Securities to be Offered to Employees
Prospectus filed pursuant to Rule 424(b)(5)
Prospectus filed pursuant to Rule 424(b)(3)
Definitive Proxy Statement
Additional Proxy Materials
Statement of Changes in Beneficial Ownership
Schedule 13G - Ownership Report
Amended Schedule 13G - Ownership Report
Notice of Proposed Sale of Securities
Submission Upload
Correspondence